Keep growing along the path of development and innovation already undertaken in recent years, and reinforce the integration with the Lugano Headquarters: with these goals, IBSA Farmaceutici changes its face and presents its new leadership, who will give a new boost both to business and the evolution of the company: Massimiliano Licenziati and Federico Mautone are the new President and the new CEO, respectively, while Giuseppe Celiberti assumes the role of General Manager.
“Over the last 5 years, IBSA Farmaceutici has quintupled its turnover, thanks to the excellent work carried out by the previous CEO & Managing Director, Luca Crippa. The new organisational layout and the new role assignments aim to keep up and consolidate the growth of the Italian subsidiary, while continuing to invest and innovate for the launch of new products and the development of cutting-edge technologies”, stated Massimiliano Licenziati upon taking on the role of new President of IBSA Farmaceutici.
IBSA Farmaceutici – the largest subsidiary of the Group – is a leading company in the Italian pharmaceutical scene, also for the quality of its research, as well as for its ability to innovate in the field of pharmaceutical technology. For these reasons, the company can give a great contribution also to the growth of the entire IBSA Group, and it is precisely following this rationale that the new corporate organisation was designed.
“The challenge we are taking up for the near future is to bring IBSA Farmaceutici to be more integrated and interconnected with the Lugano Headquarters”, affirmed Federico Mautone, Chief Executive Officer of IBSA Farmaceutici. “The year 2023 will be dedicated to facilitating this transformation, with the aim of working more within a Group perspective, where Italian skills and know-how become an important added value for the entire organisation on a global level”.
Thus, a new chapter opens in the history of IBSA Farmaceutici, which can look to the future with confidence.
“The growth we experienced over the past few years confirms the effectiveness of the choices made; we also know that we are on the right track to develop our potential even more fully and completely. For this reason, on the one hand, we will go on in the name of continuity and, on the other, we will try to seize the further opportunities offered to us by the market”, added Giuseppe Celiberti, General Manager of IBSA Farmaceutici.